Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102860 | 0.95 | NAALAD2 (0.42) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL11529406 | 0.86 | NAALAD2 (0.50) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL5461799 | 0.85 | NAALAD2 (0.42) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| Succinic Acid SCHEMBL8832713 | 0.83 | EGLN1 (0.53) | NAALAD2FFAR1CPT2TDP1LMNA | |
| Hydrochloric Acid SCHEMBL31279551 | 0.83 | NAALAD2 (0.48) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL6465628 | 0.83 | FFAR1 (0.52) | ALDH1A1MEN1KMT2AFFAR1CPT2 | |
| SCHEMBL31565174 | 0.82 | NAALAD2 (0.43) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL7083650 | 0.81 | FFAR1 (0.56) | ALDH1A1MEN1KMT2AFFAR1CPT2 | |
| SCHEMBL13168811 | 0.81 | NAALAD2 (0.46) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL14391866 | 0.80 | NAALAD2 (0.35) | NAALAD2ALDH1A1MEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3069612-A2 | DITHIOL COMPOUNDS, DERIVATIVES, AND USES THEREFOR | Encore Health, LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20150038333-A1 | PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENT -RUN FÜR GESUNDHEIT UND (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2736331-A1 | PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2014-06-04 | — | — | EP | disclosed |
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| CN-101068794-A | Quinazolines useful as modulators of ion channels | VERTEX PHARMA (US) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007071691-A1 | 3- (4-{ [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL] 0XY} PHENYL) -1-PIPERIDINYL] CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| US-5155237-A | Heating low molecular weight polylactones in presence of alkali metal, ammonium or phosphonium cations | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | NAALAD2 2689/4885ALDH1A1 2907/4885MEN1 2548/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | NAALAD2 2689/4885ALDH1A1 2907/4885MEN1 2548/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | NAALAD2 2957/4885ALDH1A1 1701/4885MEN1 3216/4885 |
| US-20150038333-A1 | PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS | HAO1, HAAO, HAO2 | NAALAD2 930/4885ALDH1A1 780/4885MEN1 3786/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | NAALAD2 459/4885ALDH1A1 3285/4885MEN1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.